Immunome Inc.

Listed Company

IMNMCIK 0001472012NasdaqNon-AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$6.94M

Net Income

$-212.39M

Total Assets

$683.19M

Equity

$634.34M

Shares Out

113.13M

Op. Cash Flow

$-190.92M

Business

Immunome Inc. is a clinical-stage targeted oncology company developing targeted therapies designed to improve outcomes for cancer patients. It develops therapeutics including antibody-drug conjugates (ADCs), a gamma secretase inhibitor (varegacestat), fibroblast activation protein-targeted radioligand therapy (IM-3050), proprietary TOP1 inhibitor payloads (HC74), linkers and related discovery assets across preclinical and clinical programs. Key business segments include ADC discovery and optimization, clinical development programs, radioligand therapy development, and intellectual property/licensing and manufacturing partnerships. Immunome conducts global clinical trials and relies on third-party manufacturers and regulatory channels across North America, Europe, Asia and Australia.

Summary from filing dated 2025-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	7	9	14	—	—
In-process research and development	10	152	81	—	—
Research and development	177	130	23	23	14
General and administrative	44	33	20	14	11
Total operating expenses	231	315	124	37	25
Loss from operations	−224	−306	−110	−37	−25
Interest income	12	13	3	5,000	−10,000
Net loss	−212	−293	−107	−37	−25
Net loss per share, basic	−2.43	−5	−5.38	−3.09	−2.14
Net loss per share, diluted	−2.43	−5	−5.38	−3.09	−2.14
Weighted-average shares outstanding, basic	87	59	20	12	12
Weighted-average shares outstanding, diluted	87	59	20	12	12
Net loss	−212	−293	−107	−38	−25
Unrealized (loss) gain on marketable securities	−57,000	35,000	—	—	—
Comprehensive loss	−212	−293	−107	−38	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	654	143	99	20	49
Marketable securities	0	74	39	—	—
Prepaid expenses and other current assets	7	4	7	2	7
Total current assets	661	221	145	23	57
Property and equipment, net	15	10	2	681,000	855,000
Operating right-of-use assets	3	4	2	284,000	500,000
Restricted cash	200,000	100,000	100,000	100,000	100,000
Other long-term assets	5	4	100,000	—	—
Total assets	683	240	149	24	58
Accounts payable	3	14	3	2	3
Accrued expenses and other current liabilities	42	33	8	5	7
Deferred revenue, current	0	7	10	—	—
Total current liabilities	45	54	22	7	10
Operating lease liabilities, net of current portion	4	5	1	—	—
Total liabilities	49	59	29	7	10
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2025 and 2024	—	—	—	—	—
Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2025 and 2024; 113,133,199 and 64,460,829 shares issued and outstanding at December 31, 2025 and 2024, respectively	11,000	6,000	4,000	1,000	1,000
Additional paid-in capital	1,362	697	343	133	127
Accumulated other comprehensive income	0	57,000	22,000	—	—
Accumulated deficit	−728	−516	−223	−116	−79
Total stockholders' equity	634	181	120	17	48
Total liabilities and stockholders' equity	683	240	149	24	58

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−212	−293	−107	−37	−25
Depreciation and amortization	3	2	500,000	400,000	800,000
Amortization of right-of-use asset	489,000	535,000	271,000	209,000	—
Accretion of discounts on marketable securities	−3	−3	−512,000	—	—
Share-based compensation expense	26	16	6	5	3
Loss on disposal of property and equipment	896,000	0	—	—	—
Charge for purchase of in-process research and development assets, including upon achievement of milestones	10	152	—	—	—
Prepaid expenses and other assets	−3	906,000	−4	5	−4
Accounts payable	−9	10	−608,000	−677,000	2
Accrued expenses and other current liabilities	5	14	614,000	−2	5
Deferred revenue	−7	−9	16	—	—
Operating lease liabilities	−166,000	−67,000	153,000	—	—
Net cash used in operating activities	−191	−111	−8	−29	−18
Maturities of marketable securities	200	155	—	—	—
Purchases of marketable securities	−123	−187	−39	—	—
Purchases of property and equipment	−10	−7	−831,000	−248,000	−79,000
Purchases of in-process research and development assets	−6	−46	—	—	—
Net cash provided by (used in) investing activities	61	−85	−30	−248,000	−79,000
Proceeds from public offerings	633	230	—	—	—
Proceeds from issuance of common stock under ATM	46	20	34,000	—	1
Payment of offering costs	−39	−15	−9	—	−222,000
Proceeds from exercise of stock options	913,000	2	371,000	32,000	99,000
Proceeds from exercise of common stock warrants	0	4	—	—	—
Net cash provided by financing activities	640	241	116	32,000	28
Net increase in cash and cash equivalents and restricted cash	510	45	78	−29	9
Purchases of in-process research and development assets, including payments owed upon achievement of development milestones, in accounts payable and accrued expenses	10	6	—	—	—
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	1	3	372,000	—	—
Remeasurement of operating right-of-use asset and lease liability due to lease modifications	811,000	2	226,000	—	—
Offering costs in accounts payable and accrued expenses and other current liabilities	364,000	0	—	—	—
Issuance of common stock in exchange for in-process research and development assets	—	98	—	—	—
Net liabilities assumed from purchases of in-process research and development assets	0	2	—	—	—
Right-of-use assets obtained in exchange for operating lease liabilities	0	1	1	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro